-
Mesenchymal stem cells in the reconstruction surgery of the supraspinatus muscle lesions
Petr Smid, Martin Komzak, Radek Hart, Libor Pasa
Research Paper: Clinical Investigation
-
Mesenchymal stem cells in the reconstruction surgery of the supraspinatus muscle lesions
Petr Smid, Martin Komzak, Radek Hart, Libor Pasa
Research Paper: Clinical Investigation
-
Mesenchymal stem cells in the reconstruction surgery of the supraspinatus muscle lesions
Petr Smid, Martin Komzak, Radek Hart, Libor Pasa
Research Paper: Clinical Investigation
-
Mesenchymal stem cells in the reconstruction surgery of the supraspinatus muscle lesions
Petr Smid, Martin Komzak, Radek Hart, Libor Pasa
Research Paper: Clinical Investigation
-
Mesenchymal stem cells in the reconstruction surgery of the supraspinatus muscle lesions
Petr Smid, Martin Komzak, Radek Hart, Libor Pasa
Research Paper: Clinical Investigation
-
Mesenchymal stem cells in the reconstruction surgery of the supraspinatus muscle lesions
Petr Smid, Martin Komzak, Radek Hart, Libor Pasa
Research Paper: Clinical Investigation
-
Mesenchymal stem cells in the reconstruction surgery of the supraspinatus muscle lesions
Petr Smid, Martin Komzak, Radek Hart, Libor Pasa
Research Paper: Clinical Investigation
-
Mesenchymal stem cells in the reconstruction surgery of the supraspinatus muscle lesions
Petr Smid, Martin Komzak, Radek Hart, Libor Pasa
Research Paper: Clinical Investigation
-
A review of randomization methods in clinical trials
Vance W Berger & Olga Antsygina
Clinical Trail Perspective: Clinical Investigation
-
A review of randomization methods in clinical trials
Vance W Berger & Olga Antsygina
Clinical Trail Perspective: Clinical Investigation
-
A review of randomization methods in clinical trials
Vance W Berger & Olga Antsygina
Clinical Trail Perspective: Clinical Investigation
-
A review of randomization methods in clinical trials
Vance W Berger & Olga Antsygina
Clinical Trail Perspective: Clinical Investigation
-
A review of randomization methods in clinical trials
Vance W Berger & Olga Antsygina
Clinical Trail Perspective: Clinical Investigation
-
A review of randomization methods in clinical trials
Vance W Berger & Olga Antsygina
Clinical Trail Perspective: Clinical Investigation
-
A review of randomization methods in clinical trials
Vance W Berger & Olga Antsygina
Clinical Trail Perspective: Clinical Investigation
-
A review of randomization methods in clinical trials
Vance W Berger & Olga Antsygina
Clinical Trail Perspective: Clinical Investigation
-
Arformoterol: rationale for use in chronic obstructive pulmonary disease
Jordan Terasaki, Shawn PE Nishi, Bill T Ameredes & Gulshan Sharm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Arformoterol: rationale for use in chronic obstructive pulmonary disease
Jordan Terasaki, Shawn PE Nishi, Bill T Ameredes & Gulshan Sharm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Arformoterol: rationale for use in chronic obstructive pulmonary disease
Jordan Terasaki, Shawn PE Nishi, Bill T Ameredes & Gulshan Sharm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Arformoterol: rationale for use in chronic obstructive pulmonary disease
Jordan Terasaki, Shawn PE Nishi, Bill T Ameredes & Gulshan Sharm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Arformoterol: rationale for use in chronic obstructive pulmonary disease
Jordan Terasaki, Shawn PE Nishi, Bill T Ameredes & Gulshan Sharm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Arformoterol: rationale for use in chronic obstructive pulmonary disease
Jordan Terasaki, Shawn PE Nishi, Bill T Ameredes & Gulshan Sharm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Arformoterol: rationale for use in chronic obstructive pulmonary disease
Jordan Terasaki, Shawn PE Nishi, Bill T Ameredes & Gulshan Sharm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Arformoterol: rationale for use in chronic obstructive pulmonary disease
Jordan Terasaki, Shawn PE Nishi, Bill T Ameredes & Gulshan Sharm
Review: Clinical Trail Outcomes: Clinical Investigation
-
Histone deacetylase inhibitors for the treatment of breast cancer: recent trial data
Thach-Giao Truong, Pamela Munster
Review: Clinical Trail Outcomes: Clinical Investigation
-
Histone deacetylase inhibitors for the treatment of breast cancer: recent trial data
Thach-Giao Truong, Pamela Munster
Review: Clinical Trail Outcomes: Clinical Investigation
-
Histone deacetylase inhibitors for the treatment of breast cancer: recent trial data
Thach-Giao Truong, Pamela Munster
Review: Clinical Trail Outcomes: Clinical Investigation
-
Histone deacetylase inhibitors for the treatment of breast cancer: recent trial data
Thach-Giao Truong, Pamela Munster
Review: Clinical Trail Outcomes: Clinical Investigation
-
Histone deacetylase inhibitors for the treatment of breast cancer: recent trial data
Thach-Giao Truong, Pamela Munster
Review: Clinical Trail Outcomes: Clinical Investigation
-
Histone deacetylase inhibitors for the treatment of breast cancer: recent trial data
Thach-Giao Truong, Pamela Munster
Review: Clinical Trail Outcomes: Clinical Investigation
-
Histone deacetylase inhibitors for the treatment of breast cancer: recent trial data
Thach-Giao Truong, Pamela Munster
Review: Clinical Trail Outcomes: Clinical Investigation
-
Histone deacetylase inhibitors for the treatment of breast cancer: recent trial data
Thach-Giao Truong, Pamela Munster
Review: Clinical Trail Outcomes: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Linagliptin tablets first to receive US FDA approval at one dosage strength for Type 2 diabetes treatment
News and Views: Clinical Investigation
-
Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data
Brendan Boyce, Lianping Xing
Review Article: Clinical Investigation
-
Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data
Brendan Boyce, Lianping Xing
Review Article: Clinical Investigation
-
Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data
Brendan Boyce, Lianping Xing
Review Article: Clinical Investigation
-
Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data
Brendan Boyce, Lianping Xing
Review Article: Clinical Investigation
-
Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data
Brendan Boyce, Lianping Xing
Review Article: Clinical Investigation
-
Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data
Brendan Boyce, Lianping Xing
Review Article: Clinical Investigation
-
Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data
Brendan Boyce, Lianping Xing
Review Article: Clinical Investigation
-
Src inhibitors in the treatment of metastatic bone disease: rationale and clinical data
Brendan Boyce, Lianping Xing
Review Article: Clinical Investigation
-
Chemoprevention of prostate cancer: is there evidence from clinical trials?
Marcelo Langer Wroclawski, Cynthia Kuk, Antonio Finelli, Neil E Fleshner, Alexandre R Zlotta
Therapeutic Prospective: Clinical Investigation
-
Chemoprevention of prostate cancer: is there evidence from clinical trials?
Marcelo Langer Wroclawski, Cynthia Kuk, Antonio Finelli, Neil E Fleshner, Alexandre R Zlotta
Therapeutic Prospective: Clinical Investigation
-
Chemoprevention of prostate cancer: is there evidence from clinical trials?
Marcelo Langer Wroclawski, Cynthia Kuk, Antonio Finelli, Neil E Fleshner, Alexandre R Zlotta
Therapeutic Prospective: Clinical Investigation
-
Chemoprevention of prostate cancer: is there evidence from clinical trials?
Marcelo Langer Wroclawski, Cynthia Kuk, Antonio Finelli, Neil E Fleshner, Alexandre R Zlotta
Therapeutic Prospective: Clinical Investigation
-
Chemoprevention of prostate cancer: is there evidence from clinical trials?
Marcelo Langer Wroclawski, Cynthia Kuk, Antonio Finelli, Neil E Fleshner, Alexandre R Zlotta
Therapeutic Prospective: Clinical Investigation
-
Chemoprevention of prostate cancer: is there evidence from clinical trials?
Marcelo Langer Wroclawski, Cynthia Kuk, Antonio Finelli, Neil E Fleshner, Alexandre R Zlotta
Therapeutic Prospective: Clinical Investigation
-
Chemoprevention of prostate cancer: is there evidence from clinical trials?
Marcelo Langer Wroclawski, Cynthia Kuk, Antonio Finelli, Neil E Fleshner, Alexandre R Zlotta
Therapeutic Prospective: Clinical Investigation
-
Chemoprevention of prostate cancer: is there evidence from clinical trials?
Marcelo Langer Wroclawski, Cynthia Kuk, Antonio Finelli, Neil E Fleshner, Alexandre R Zlotta
Therapeutic Prospective: Clinical Investigation